Phase I Study of Lysine-Specific Demethylase-1 Inhibitor CC-90011 in Patients With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma.

CONCLUSIONS: CC-90011 is well-tolerated, with the RP2D established as 60 mg QW. The MTD and NTD were determined to be 80 mg QW and 120 mg QW, respectively. Further evaluation of CC-90011 is warranted.
PMID: 33046517 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - October 12, 2020 Category: Cancer & Oncology Authors: Hollebecque A, Salvagni S, Plummer R, Isambert N, Niccoli P, Capdevila J, Curigliano G, Moreno V, Martin-Romano P, Baudin E, Arias M, Mora S, de Alvaro J, Di Martino J, Parra-Palau JL, Sánchez-Pérez T, Aronchik I, Filvaroff EH, Lamba M, Nikolova Z, de B Tags: Clin Cancer Res Source Type: research